AndreaCercekMD

Instructor, Medicine, Weill Cornell Medical College

Overview of Dr. Cercek

Dr. Andrea Cercek is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, New York-Presbyterian Hospital, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from New York Medical College and has been in practice 13 years. She is one of 503 doctors at Memorial Sloan Kettering Cancer Center and one of 62 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. She also speaks multiple languages, including Spanish. She has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(231) 508-9752

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2007
New York Medical CollegeClass of 2004

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2006 - 2026
CT State Medical License 2024 - 2025
NJ State Medical License 2020 - 2025
NC State Medical License 2020 - 2022
American Board of Internal Medicine Medical Oncology

Clinical Trials

Clinical and Translational Study of STA-9090 Start of enrollment: 2010 Apr 01
Completed
Phase 2
A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours Start of enrollment: 2011 Jan 01
Completed
Phase 1
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma Start of enrollment: 2013 Sep 05
Completed
Phase 1
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
ACTIVE_NOT_RECRUITING
PHASE2
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Start of enrollment: 2017 Jun 23
COMPLETED
PHASE2
Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver Start of enrollment: 2017 Feb 28
Withdrawn
Phase 2
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma Start of enrollment: 2017 Oct 05
Terminated
Phase 1, Phase 2
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial Start of enrollment: 2020 Apr 20
Terminated
Collection of Information to Better Understand Young Onset Colorectal Cancer Start of enrollment: 2020 Jul 22
RECRUITING
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery Start of enrollment: 2021 May 07
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.
Jeremy Sharib, Kristen E Rhodin, Annie Liu, Sarah McIntyre, Alex Bartholomew
Annals of Surgical Oncology. 2025-04-01
ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic Cholangiocarcinoma.
Jeremy Sharib, Kristen E Rhodin, Annie Liu, Sarah McIntyre, Alex Bartholomew
Annals of Surgical Oncology. 2025-04-01
Utilizing Patient Input in Rectal Cancer Trial Design.
Janet Alvarez, Wini Zambare, Manju George, Reese Garcia, Phuong Gallagher
Journal of the National Cancer Institute. 2025-03-19

Journal Articles

Locoregional Therapy plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma—Reply
Andrea Cercek, MD, JAMA Oncology
Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits
Jinru Shia, Garrett M Nash, Philip B Paty, Andrea Cercek, Campbell S Roxburgh, Annals of Surgical Oncology
Pelvic MRI After Induction Chemotherapy and Before Long-Course Chemoradiation Therapy for Rectal Cancer: What Are the Imaging Findings?
Andrea Cercek, Leonard Saltz, Marc J Gollub, Patricio Lynn, Martin R Weiser, European Radiology
Quantitative Imaging Features of Pretreatment CT Predict Volumetric Response to Chemotherapy in Patients with Colorectal Liver Metastases
Andrea Cercek, William R Jarnagin, Jinru Shia, Peter J Allen, Kenneth P Seastedt, Nancy E Kemeny, Ronald P DeMatteo, Vinod P Balachandran, T Peter Kingham, European Radiology
Join now to see all

Lectures

Gastrointestinal (Colorectal) Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Prevalence of germline genetic alterations in colorectal cancer patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Locoregional Therapy plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma—ReplyApril 2020

Press Mentions

Lifesaving Cancer Study Delivers Complete Remission for All Trial PatientsMarch 6th, 2025
FDA Approved Drug Achieves 100% Remission for Rectal CancerDecember 31st, 2024
Groundbreaking Clinical Trial Cures Cancer in 100% of PatientsNovember 20th, 2024
Join now to see all

Grant Support

Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal CancerSLOAN-KETTERING INST CAN RESEARCH2024–2029
Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancerSLOAN-KETTERING INST CAN RESEARCH2022–2027
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)SLOAN-KETTERING INST CAN RESEARCH2020–2025